2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T489,A total of 144 participants (mean [SD] age, 42.6 [10.8] years; 85 male [59.0%]) were randomized, and 142 were included in the primary efficacy analysis: psilocybin, 25 mg (n = 47), psilocybin, 5 mg (n = 48), and nicotinamide (n = 47). Response rates on the primary end point were 17.0% in the group receiving psilocybin, 25 mg; 12.5% in the group receiving psilocybin, 5 mg; and 10.6% in the group receiving nicotinamide. The first hierarchical comparison was nonsignificant (psilocybin, 25 mg vs nicotinamide, adjusted odds ratio [OR], 1.73; 95% CI, 0.53-6.23; P = .19; 1-sided α P = .03); consequently, further formal testing was not performed. Analyses of key secondary end points (mean changes from baseline on HAMD17 and BDI-II) provided exploratory evidence of a clinically meaningful effect of psilocybin, 25 mg. Psilocybin, 25 mg, was linked to adverse events, predominantly acutely, and was associated with higher reports of suicidal ideation on dosing days (4% vs 1%-2% in comparator conditions). Two serious adverse reactions were reported after psilocybin, 25 mg, including 1 case of hallucinogen persisting perception disorder.31:Tbef,Psilocybin shows promise in treating depression, although limitations of previous research warrant further research. To investigate the efficacy and safety of oral psilocybin, 25 mg, with adjunct psychotherapy in treatment-resistant depression (TRD). This was a 2-center, triple-blinded (investigator, participant, rater), phase 2b, active placebo-controlled randomized clinical trial. Participants were randomized to 4 groups in ratios 2:2:1:1, receiving 2 doses 6 weeks apart (week 0, week 6) as follows: (1) placebo (nicotinamide, 100 mg) then psilocybin, 25 mg; (2) psilocybin, 5 mg, then 25 mg; and (3) psilocybin, 25 mg, then 5 mg or psilocybin, 25 mg, twice embedded in psychotherapeutic sessions. Participants aged 25 to 65 years with TRD and withdrawn from antidepressant medication were recruited predominantly from 2 outpatient settings in Germany. Study data were analyzed from April 2024 to November 2025. Oral synthetic psilocybin, 25 mg; psilocybin, 5 mg; or nicotinamide, 100 mg administered with psychotherapeutic sessions. The primary end point was treatment response (≥50% reduction on the Hamilton Rating Scale for Depression [HAMD17]) at week 6 before the second dose. Key secondary end points were response on the Beck Depression Inventory II (BDI-II) and mean change from baseline on the HAMD17 and BDI-II at week 6. A total of 144 participants (mean [SD] age, 42.6 [10.8] years; 85 male [59.0%]) were randomized, and 142 were included in the primary efficacy analysis: psilocybin, 25 mg (n = 47), psilocybin, 5 mg (n = 48), and nicotinamide (n = 47). Response rates on the primary end point were 17.0% in the group receiving psilocybin, 25 mg; 12.5% in the group receiving psilocybin, 5 mg; and 10.6% in the group receiving nicotinamide. The first hierarchical comparison was nonsignificant (psilocybin, 25 mg vs nicotinamide, adjusted odds ratio [OR], 1.73; 95% CI, 0.53-6.23; P = .19; 1-sided α P = .03); consequently, further formal testing was not performed. Analyses of key secondary end points (mean changes from baseline on HAMD17 and BDI-II) provided exploratory evidence of a clinically meaningful effect of psilocybin, 25 mg. Psilocybin, 25 mg, was linked to adverse events, predominantly acutely, and was associated with higher reports of suicidal ideation on dosing days (4% vs 1%-2% in comparator conditions). Two serious adverse reactions were reported after psilocybin, 25 mg, including 1 case of hallucinogen persisting perception disorder. In this randomized clinical trial, psilocybin, 25 mg, with adjunct psychotherapy, was associated with a clinically meaningful reduction in depressive symptoms in individuals with TRD, although findings did not show a significant effect on the primary outcome. The treatment was well tolerated by most participants, although safety signals were observed. While overall this constituted an inconclusive trial, these results add to the existing evidence on the potential of psilocybin treatment for depression. ClinicalTrials.gov Identifier: NCT04670081.32:T126e, Importance Psilocybin shows promise in treating depression, although limitations of previous research warrant further research. Objective To investigate the efficacy and safety of oral psilocybin, 25 mg, with adjunct psychotherapy in treatment-resistant depression (TRD). Design, Setting, and Participants This was a 2-center, triple-blinded (investigator, participant, rater), phase 2b, active placebo-controlled randomized clinical trial. Participants were randomized to 4 groups in ratios 2:2:1:1, receiving 2 doses 6 weeks apart (week 0, week 6) as follows: (1) placebo (nicotinamide, 100 mg) then psilocybin, 25 mg; (2) psilocybin, 5 mg, then 25 mg; and (3) psilocybin, 25 mg, then 5 mg or psilocybin, 25 mg, twice embedded in psychotherapeutic sessions. Participants aged 25 to 65 years with TRD and withdrawn from antidepressant medication were recruited predominantly from 2 outpatient settings in Germany. Study data were analyzed from April 2024 to November 2025. Interventions Oral synthetic psilocybin, 25 mg; psilocybin, 5 mg; or nicotinamide, 100 mg administered with psychotherapeutic sessions. Main Outcomes and Measures The primary end point was treatment response (≥50% reduction on the Hamilton Rating Scale for Depression [HAMD17]) at week 6 before the second dose. Key secondary end points were response on the Beck Depression Inventory II (BDI-II) and mean change from baseline on the HAMD17 and BDI-II at week 6. Results A total of 144 participants (mean [SD] age, 42.6 [10.8] years; 85 male [59.0%]) were randomized, and 142 were included in the primary efficacy analysis: psilocybin, 25 mg (n = 47), psilocybin, 5 mg (n = 48), and nicotinamide (n = 47). Response rates on the primary end point were 17.0% in the group receiving psilocybin, 25 mg; 12.5% in the group receiving psilocybin, 5 mg; and 10.6% in the group receiving nicotinamide. The first hierarchical comparison was nonsignificant (psilocybin, 25 mg vs nicotinamide, adjusted odds ratio [OR], 1.73; 95% CI, 0.53-6.23; P = .19; 1-sided α P = .03); consequently, further formal testing was not performed. Analyses of key secondary end points (mean changes from baseline on HAMD17 and BDI-II) provided exploratory evidence of a clinically meaningful effect of psilocybin, 25 mg. Psilocybin, 25 mg, was linked to adverse events, predominantly acutely, and was associated with higher reports of suicidal ideation on dosing days (4% vs 1%-2% in comparator conditions). Two serious adverse reactions were reported after psilocybin, 25 mg, including 1 case of hallucinogen persisting perception disorder. Conclusion and Relevance In this randomized clinical trial, psilocybin, 25 mg, with adjunct psychotherapy, was associated with a clinically meaningful reduction in depressive symptoms in individuals with TRD, although findings did not show a significant effect on the primary outcome. The treatment was well tolerated by most participants, although safety signals were observed. While overall this constituted an inconclusive trial, these results add to the existing evidence on the potential of psilocybin treatment for depression. Trial Registration ClinicalTrials.gov Identifier: NCT04670081 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Psychedelic-Assisted Psychotherapy: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Psychedelic-Assisted Psychotherapy (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Psychedelic-Assisted%20Psychotherapy\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Psychedelic-Assisted Psychotherapy\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Psychedelic-Assisted%20Psychotherapy\"}]}}"}}]],["$","$L2f",null,{"title":"Psychedelic-Assisted Psychotherapy: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Psychedelic-Assisted Psychotherapy — concise summaries and practical next steps.","papers":[{"doi":"10.1001/jamanetworkopen.2026.12589","pmid":"42138922","title":"Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression","journal_title":"JAMA Network Open","journal_issn":"2574-3805","published_at":"2026-05-15T00:00:00.000Z","url":"https://doi.org/10.1001/jamanetworkopen.2026.12589","source_score":183,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-21T13:20:55.004Z","updated_at":"2026-05-21T13:20:55.004Z","tags":[{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"condition","value":"Major Depressive Disorder","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"generic","value":"niacin","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"generic","value":"psilocybin","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"modality","value":"Psychedelic-Assisted Psychotherapy","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"sample_size","value":"n=35","value_numeric":35},{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"warning","value":"Active placebo (niacin) may not have fully blinded participants, potentially inflating effect sizes due to expectation bias.","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"warning","value":"Small sample size (n=35) means the trial was likely underpowered to detect rare adverse events or long-term efficacy differences.","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.12589","tag_type":"warning","value":"The 1-year follow-up allowed open-label treatment crossover or additional interventions — between-group comparisons at day 365 should be interpreted with caution.","value_numeric":null}],"summaries":{"what_studied":"A double-blind, placebo-controlled RCT (n=35) evaluated a single 25 mg dose of psilocybin vs. active placebo (niacin 100 mg) plus 5 psychotherapy support sessions in adults with moderate-to-severe recurrent MDD, with follow-up through 365 days (Stockholm, 2021–2024).","key_result":"Psilocybin met its primary endpoint: MADRS scores dropped significantly more than placebo by day 8 (mean difference −7.27; 95% CI −12.89 to −1.65; P=.01), with effects persisting through day 42 (P=.004) but not day 365 (P=.20). Self-reported symptoms (MADRS-S) showed benefit as early as day 2 and through day 102; 2 of 17 psilocybin participants had persistent severe anxiety requiring medical attention.","limitations":"- Very small sample (n=35), limiting power for subgroup and safety analyses.\n- Single-site study in Sweden may restrict generalizability.\n- Between-group difference lost significance at 1 year, and the trial was not powered for long-term outcomes.","practice_takeaway":"A single dose of psilocybin (25 mg) with psychotherapy support produced rapid (onset day 2) and sustained (>3 months) antidepressant effects in recurrent MDD, but effects faded by 1 year — clinicians should be aware that some patients may need additional anxiety support post-dosing, and that repeated or adjunctive strategies may be needed for durability."}},{"doi":"10.1001/jamapsychiatry.2026.0132","pmid":"41848690","title":"Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression","journal_title":"JAMA Psychiatry","journal_issn":"2168-622X","published_at":"2026-03-18T00:00:00.000Z","url":"https://doi.org/10.1001/jamapsychiatry.2026.0132","source_score":532,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-05-11","doi":"10.1001/jamapsychiatry.2026.0132","days":"7","issn":"2168-622X","rank":"1","field":"Clinical Medicine","score":"532","category":"Psychiatry","categories":["Psychiatry"],"_categories":["Psychiatry"]},"pubmed":{"doi":"10.1001/jamapsychiatry.2026.0132","title":"Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.","journal":"JAMA psychiatry","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"41848690","conclusions":"","publication_date":"2026-03-18T00:00:00"},"crossref":{"DOI":"10.1001/jamapsychiatry.2026.0132","URL":"https://doi.org/10.1001/jamapsychiatry.2026.0132","ISSN":["2168-622X"],"link":[{"URL":"https://jamanetwork.com/journals/jamapsychiatry/articlepdf/2846478/jamapsychiatry_mertens_2026_oi_260007_1777052914.3703.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"448","type":"journal-article","issue":"5","score":1,"title":["Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression"],"author":[{"given":"Lea J.","family":"Mertens","sequence":"first","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"}]},{"given":"Michael","family":"Koslowski","sequence":"additional","affiliation":[{"name":"Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany"},{"name":"German Center for Mental Health, partner site Berlin-Potsdam, Berlin, Germany"}]},{"given":"Felix","family":"Betzler","sequence":"additional","affiliation":[{"name":"Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany"},{"name":"German Center for Mental Health, partner site Berlin-Potsdam, Berlin, Germany"}]},{"given":"Manuela","family":"Brand","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"}]},{"given":"Ricarda","family":"Evens","sequence":"additional","affiliation":[{"name":"Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany"},{"name":"Department of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany"}]},{"given":"Laura","family":"Kärtner","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"}]},{"given":"Andrea","family":"Jungaberle","sequence":"additional","affiliation":[{"name":"Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany"},{"name":"MIND Foundation, Berlin, Germany"},{"name":"OVID Health Systems GmbH, Berlin, Germany"}]},{"given":"Henrik","family":"Jungaberle","sequence":"additional","affiliation":[{"name":"MIND Foundation, Berlin, Germany"},{"name":"OVID Health Systems GmbH, Berlin, Germany"}]},{"given":"Tomislav","family":"Majić","sequence":"additional","affiliation":[{"name":"Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany"},{"name":"German Center for Mental Health, partner site Berlin-Potsdam, Berlin, Germany"}]},{"given":"Christian N.","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}]},{"given":"Andreas","family":"Ströhle","sequence":"additional","affiliation":[{"name":"Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany"}]},{"given":"Dennis","family":"Scharf","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}]},{"given":"Moritz","family":"Spangemacher","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}]},{"given":"Max","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany"},{"name":"MIND Foundation, Berlin, Germany"},{"name":"OVID Health Systems GmbH, Berlin, Germany"}]},{"given":"Zahra","family":"Assadi","sequence":"additional","affiliation":[{"name":"Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany"}]},{"given":"Scharif","family":"Bahri","sequence":"additional","affiliation":[{"name":"Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany"}]},{"given":"Lilith","family":"Becher","sequence":"additional","affiliation":[{"name":"Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany"}]},{"given":"Luca V.","family":"Färber","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"}]},{"given":"Niklas","family":"Kirchen","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}]},{"given":"Eugenia","family":"Kulakova","sequence":"additional","affiliation":[{"name":"Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany"},{"name":"German Center for Mental Health, partner site Berlin-Potsdam, Berlin, Germany"}]},{"given":"Linda","family":"Kunz","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}]},{"given":"Andy","family":"Meijer","sequence":"additional","affiliation":[{"name":"Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany"}]},{"given":"Barbara","family":"Rohrmoser","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}]},{"given":"Stefan","family":"Wellek","sequence":"additional","affiliation":[{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Core Facility of Biostatistics, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}]},{"given":"Moritz M.","family":"Berger","sequence":"additional","affiliation":[{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Core Facility of Biostatistics, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}]},{"given":"Gerhard","family":"Gründer","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"OVID Health Systems GmbH, Berlin, Germany"}]}],"issued":{"date-parts":[[2026,5,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"83","created":{"date-time":"2026-03-18T15:30:36Z","timestamp":1773847836000,"date-parts":[[2026,3,18]]},"indexed":{"date-time":"2026-05-12T01:11:37Z","timestamp":1778548297261,"date-parts":[[2026,5,12]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2846478"}},"subtitle":["The EPISODE Randomized Clinical Trial"],"deposited":{"date-time":"2026-05-06T15:00:39Z","timestamp":1778079639000,"date-parts":[[2026,5,6]]},"issn-type":[{"type":"print","value":"2168-622X"}],"published":{"date-parts":[[2026,5,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/S0140-6736(24)00757-8","key":"yoi260007r2","year":"2024","issue":"10440","author":"Ferrari","volume":"403","first-page":"2133","unstructured":null,"article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamapsychiatry.2022.3860","key":"yoi260007r5","year":"2023","issue":"2","author":"Lundberg","volume":"80","first-page":"167","unstructured":null,"article-title":"Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study.","journal-title":"JAMA Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12888-019-2222-4","key":"yoi260007r6","year":"2019","issue":"1","author":"Jaffe","volume":"19","first-page":"247","unstructured":null,"article-title":"The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study.","journal-title":"BMC Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1016/S2215-0366(16)30065-7","key":"yoi260007r7","year":"2016","issue":"7","author":"Carhart-Harris","volume":"3","first-page":"619","unstructured":null,"article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.","journal-title":"Lancet Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.medj.2024.01.005","key":"yoi260007r8","year":"2024","issue":"3","author":"Rosenblat","volume":"5","first-page":"190","unstructured":null,"article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin.","journal-title":"Med","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamapsychiatry.2020.3285","key":"yoi260007r9","year":"2021","issue":"5","author":"Davis","volume":"78","first-page":"481","unstructured":null,"article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial.","journal-title":"JAMA Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eclinm.2022.101809","key":"yoi260007r10","year":"2022","issue":null,"author":"von Rotz","volume":"56","first-page":null,"unstructured":null,"article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomized clinical trial.","journal-title":"EClinicalMedicine","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2023.14530","key":"yoi260007r11","year":"2023","issue":"9","author":"Raison","volume":"330","first-page":"843","unstructured":null,"article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2206443","key":"yoi260007r12","year":"2022","issue":"18","author":"Goodwin","volume":"387","first-page":"1637","unstructured":null,"article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2032994","key":"yoi260007r13","year":"2021","issue":"15","author":"Carhart-Harris","volume":"384","first-page":"1402","unstructured":null,"article-title":"Trial of psilocybin vs escitalopram for depression.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj-2023-078084","key":"yoi260007r14","year":"2024","issue":null,"author":"Metaxa","volume":"385","first-page":null,"unstructured":null,"article-title":"Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.nsa.2022.100104","key":"yoi260007r15","year":"2022","issue":null,"author":"Mertens","volume":"1","first-page":null,"unstructured":null,"article-title":"Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE)—rationale and study design.","journal-title":"Neurosci Appl","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMc2108082","key":"yoi260007r16","year":"2021","issue":"9","author":"Gründer","volume":"385","first-page":"863","unstructured":null,"article-title":"Psilocybin for depression.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00213-022-06123-7","key":"yoi260007r17","year":"2022","issue":"6","author":"Aday","volume":"239","first-page":"1989","unstructured":null,"article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.","journal-title":"Psychopharmacology (Berl)","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamapsychiatry.2024.2546","key":"yoi260007r18","year":"2024","issue":"12","author":"Hinkle","volume":"81","first-page":"1225","unstructured":null,"article-title":"Adverse events in studies of classic psychedelics: a systematic review and meta-analysis.","journal-title":"JAMA Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1136/jnnp.23.1.56","key":"yoi260007r19","year":"1960","issue":"1","author":"Hamilton","volume":"23","first-page":"56","unstructured":null,"article-title":"A rating scale for depression.","journal-title":"J Neurol Neurosurg Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1080/09540261.2018.1486289","key":"yoi260007r20","year":"2018","issue":"4","author":"Garcia-Romeu","volume":"30","first-page":"291","unstructured":null,"article-title":"Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.","journal-title":"Int Rev Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1177/0269881108093587","key":"yoi260007r21","year":"2008","issue":"6","author":"Johnson","volume":"22","first-page":"603","unstructured":null,"article-title":"Human hallucinogen research: guidelines for safety.","journal-title":"J Psychopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1177/0269881116675512","key":"yoi260007r22","year":"2016","issue":"12","author":"Ross","volume":"30","first-page":"1165","unstructured":null,"article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","journal-title":"J Psychopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00213-011-2358-5","key":"yoi260007r23","year":"2011","issue":"4","author":"Griffiths","volume":"218","first-page":"649","unstructured":null,"article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.","journal-title":"Psychopharmacology (Berl)","doi-asserted-by":"publisher"},{"DOI":"10.1016/0272-7358(88)90050-5","key":"yoi260007r25","year":"1988","issue":null,"author":"Beck","volume":"8","first-page":"77","unstructured":null,"article-title":"Psychometric properties of the Beck depression inventory: twenty-five years of evaluation.","journal-title":"Clin Psychol Rev","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmjebm-2020-111600","key":"yoi260007r26","year":"2022","issue":"2","author":"Hengartner","volume":"27","first-page":"69","unstructured":null,"article-title":"Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression.","journal-title":"BMJ Evid Based Med","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1600-0447.1987.tb10566.x","key":"yoi260007r27","year":"1987","issue":null,"author":"Lingjaerde","volume":"334","first-page":"1","unstructured":null,"article-title":"The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.","journal-title":"Acta Psychiatr Scand Suppl","doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.2011.10111704","key":"yoi260007r28","year":"2011","issue":"12","author":"Posner","volume":"168","first-page":"1266","unstructured":null,"article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from 3 multisite studies with adolescents and adults.","journal-title":"Am J Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1016/S2215-0366(23)00363-2","key":"yoi260007r31","year":"2024","issue":"3","author":"Gründer","volume":"11","first-page":"231","unstructured":null,"article-title":"Treatment with psychedelics is psychotherapy: beyond reductionism.","journal-title":"Lancet Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1177/20451253231172254","key":"yoi260007r32","year":"2023","issue":null,"author":"Evens","volume":"13","first-page":null,"unstructured":null,"article-title":"The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics.","journal-title":"Ther Adv Psychopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.3238/arztebl.m2024.0224","key":"yoi260007r33","year":"2024","issue":"26","author":"Spangemacher","volume":"121","first-page":"868","unstructured":null,"article-title":"Psilocybin as a disease-modifying drug—a salutogenic approach in psychiatry.","journal-title":"Dtsch Arztebl Int","doi-asserted-by":"publisher"},{"DOI":"10.1521/pedi_2013_27_070","key":"yoi260007r34","year":"2014","issue":"4","author":"Newton-Howes","volume":"28","first-page":"577","unstructured":null,"article-title":"Influence of personality on the outcome of treatment in depression: systematic review and meta-analysis.","journal-title":"J Pers Disord","doi-asserted-by":"publisher"},{"DOI":"10.1016/S2215-0366(20)30099-7","key":"yoi260007r35","year":"2020","issue":"9","author":"Schramm","volume":"7","first-page":"801","unstructured":null,"article-title":"Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications.","journal-title":"Lancet Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1176/ajp.2006.163.11.1905","key":"yoi260007r36","year":"2006","issue":"11","author":"Rush","volume":"163","first-page":"1905","unstructured":null,"article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","journal-title":"Am J Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamapsychiatry.2022.2096","key":"yoi260007r37","year":"2022","issue":"10","author":"Bogenschutz","volume":"79","first-page":"953","unstructured":null,"article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial.","journal-title":"JAMA Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1742-1241.2005.00440.x","key":"yoi260007r38","year":"2005","issue":"3","author":"Llorca","volume":"59","first-page":"268","unstructured":null,"article-title":"Efficacy of escitalopram in patients with severe depression: a pooled analysis.","journal-title":"Int J Clin Pract","doi-asserted-by":"publisher"},{"DOI":"10.1080/17512433.2021.1933434","key":"yoi260007r39","year":"2021","issue":"9","author":"Muthukumaraswamy","volume":"14","first-page":"1133","unstructured":null,"article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials.","journal-title":"Expert Rev Clin Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1098/rstb.2010.0394","key":"yoi260007r40","year":"2011","issue":"1572","author":"Mora","volume":"366","first-page":"1879","unstructured":null,"article-title":"Lessons learned from placebo groups in antidepressant trials.","journal-title":"Philos Trans R Soc Lond B Biol Sci","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2025.24119","key":"yoi260007r41","year":"2025","issue":"7","author":"Hieronymus","volume":"8","first-page":"e2524119","unstructured":null,"article-title":"Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression: a meta-analysis.","journal-title":"JAMA Netw Open","doi-asserted-by":"publisher"},{"DOI":null,"key":"yoi260007r24","year":null,"issue":null,"author":"Schmitt","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"yoi260007r1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Vizhub Health Data. Evaluation IfHM—Global Health Data Exchange (GHDx). Accessed October 12, 2024.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"yoi260007r3","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"European Medicines Agency (EMA). Guideline on clinical investigation of medicinal products in the treatment of depression—revision 2. Accessed December 18, 2024. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-2_en.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"yoi260007r4","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"US Food and Drug Administration (FDA). Major depressive disorder: developing drugs for treatment—guidance for industry (revision 1). Accessed December 18, 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/major-depressive-disorder-developing-drugs-treatment","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"yoi260007r29","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"SAS Institute. SAS/STAT 9.4 support, version 9.4. Accessed April 15, 2024. https://support.sas.com/en/software/sas-stat-support.html","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"yoi260007r30","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"R Project. The R project for statistical computing, version 4.4. Accessed April 15, 2024. https://www.R-project.org/","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,5,1]]},"reference-count":41,"published-online":null,"references-count":41,"short-container-title":["JAMA Psychiatry"],"is-referenced-by-count":4},"unpaywall":{"doi":"10.1001/jamapsychiatry.2026.0132","is_oa":true,"title":"Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression","updated":"2026-03-22T08:27:26+00:00","published_date":"2026-03-18","best_oa_location":{"url":"https://jamanetwork.com/journals/jamapsychiatry/articlepdf/2846478/jamapsychiatry_mertens_2026_oi_260007_1773063218.23381.pdf","pmh_id":null,"url_for_pdf":"https://jamanetwork.com/journals/jamapsychiatry/articlepdf/2846478/jamapsychiatry_mertens_2026_oi_260007_1773063218.23381.pdf","url_for_landing_page":"https://doi.org/10.1001/jamapsychiatry.2026.0132"}}},"created_at":"2026-05-12T13:18:07.361Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"category","value":"Psychiatry","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"condition","value":"Major Depressive Disorder","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"condition","value":"Treatment-Resistant Depression","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"generic","value":"nicotinamide","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"generic","value":"psilocybin","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"modality","value":"Psychedelic-Assisted Psychotherapy","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"sample_size","value":"n=144","value_numeric":144},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"warning","value":"Nicotinamide (100 mg) was used as an active placebo; its physiological activity may not be fully inert, which could affect placebo response rates.","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"warning","value":"Suicidal ideation signal on dosing days (4% in psilocybin 25 mg vs. 1–2% in comparators) is a material safety finding but absolute event counts are not specified in the abstract.","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"warning","value":"The paper is dated 2026 and is not yet verifiable as published; content is based solely on the provided abstract text.","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0132","tag_type":"warning","value":"The trial used an unusual 2:2:1:1 randomization ratio across 4 groups, but the primary efficacy analysis collapsed to 3 arms (n=47, 48, 47); the fourth group's allocation is not fully clarified in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Phase 2b triple-blinded RCT in 144 adults (aged 25–65) with treatment-resistant major depression (TRD) off antidepressants, comparing oral psilocybin 25 mg vs. 5 mg vs. active placebo (nicotinamide 100 mg), each given with adjunct psychotherapy at 2 German outpatient centers; primary endpoint was ≥50% HAMD17 reduction at week 6.","key_result":"Response rates at week 6 were 17.0% (psilocybin 25 mg), 12.5% (psilocybin 5 mg), and 10.6% (nicotinamide); the primary comparison was non-significant (OR 1.73; 95% CI 0.53–6.23; P = .19). Secondary endpoint analyses (HAMD17 and BDI-II mean change) showed exploratory but not formally tested evidence of a clinically meaningful benefit with psilocybin 25 mg.","limitations":"- Trial was underpowered or inconclusive: the primary endpoint did not reach significance, halting further formal testing in the hierarchy.\n- Small sample size (n=47 per key arm) limits ability to detect modest effect sizes.\n- Blinding integrity is uncertain given psilocybin's distinctive subjective effects, despite triple-blind design.","practice_takeaway":"Psilocybin 25 mg with psychotherapy did not significantly outperform active placebo for TRD in this trial and carried safety signals including suicidal ideation on dosing days (4%) and a case of hallucinogen persisting perception disorder — clinicians should not yet adopt this as standard care. Exploratory secondary data suggest possible benefit, supporting the need for larger, adequately powered trials."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Psychedelic-Assisted Psychotherapy"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Psychedelic-Assisted Psychotherapy"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Psychedelic-Assisted Psychotherapy"}}}]]

Papers